R
Richard B. Kim
Researcher at University of Western Ontario
Publications - 380
Citations - 33088
Richard B. Kim is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 89, co-authored 328 publications receiving 30436 citations. Previous affiliations of Richard B. Kim include London Health Sciences Centre & St. Jude Children's Research Hospital.
Papers
More filters
Posted ContentDOI
Tumor response-speed heterogeneity as a novel prognostic factor in patients with mCRC
TL;DR: Tumor response-speed heterogeneity to first-line chemotherapy was a novel prognostic factor associated with early disease progression and shorter survival in patients with mCRC.
Journal ArticleDOI
A phase II study of TAS-102 (FTD/TPI) in combination with ramucirumab (RAM) in advanced, refractory gastric (GC) or gastroesophageal junction (GEJ) adenocarcinomas (GEAs).
Rutika Mehta,Richard B. Kim,Maria E Martinez Jimenez,Kirsten Blue,Trenton Avriett,Emily Kelbert,K Miller,Christopher Ray,Tiffany Valone,Woojoo Lee,Young-Chul Kim,Dae-Won Kim +11 more
TL;DR: The combination of RAM and TAS-102 showed very similar disease control rate as the study in Asia and should be investigated further now in the context of patients receiving immunotherapy-based treatment as first-line treatment.
Journal ArticleDOI
Core homologous recombination mutations and improved survival in nonpancreatic GI cancers.
Elaine Tan,Junmin Whiting,Christine M. Walko,Todd C. Knepper,Hao Xie,Iman Imanirad,Estrella M. Carballido,Seth Felder,Jessica M. Frakes,Qianxing Mo,Jennifer B. Permuth,Richard B. Kim,Daniel A. Anaya,Jason B. Fleming,Ibrahim Sahin +14 more
TL;DR: In stage IV nonpancreatic GI malignancies treated with platinum therapy, patients with core HRM had a greater OS and PFS compared to those with noncore HRM, suggesting a potential prognostic and predictive role of these mutations.
Clinical Research Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin
TL;DR: In this paper, the efficacy of nondaily rosuvastatin in previously statin-intolerant patients and determined plasma drug concentrations at various dose regimens were examined and compared.
Journal ArticleDOI
Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres.
Premsai Kumar,Rahul Mhaskar,Richard B. Kim,Daniel Anaya,Jessica M. Frakes,Sarah E. Hoffe,Jun-Ryeoul Choi,Bela Kis +7 more
TL;DR: In this article , the authors evaluated the efficacy of radiation segmentectomy/lobectomy using Y90-labeled glass microspheres in patients with; unresectable intrahepatic, cholangiocarcinoma (IHC).